Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)
Blue Earth Therapeutics Ltd
Pathos AI, Inc.
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Cedars-Sinai Medical Center
K36 Therapeutics, Inc.
M.D. Anderson Cancer Center
Atavistik Bio, Inc
Varian, a Siemens Healthineers Company
M.D. Anderson Cancer Center
University of California, Davis
National Institutes of Health Clinical Center (CC)
University of California, Irvine
Indiana University
H. Lee Moffitt Cancer Center and Research Institute
DL Analytics
Dana-Farber Cancer Institute
AgonOx, Inc.
Memorial Sloan Kettering Cancer Center
RenJi Hospital
M.D. Anderson Cancer Center
Eli Lilly and Company
The Netherlands Cancer Institute
Queen Mary University of London
University of California, San Francisco
NiKang Therapeutics, Inc.
British Columbia Cancer Agency
University of Miami
The Netherlands Cancer Institute
Dana-Farber Cancer Institute
Milton S. Hershey Medical Center
Ottawa Hospital Research Institute
Marengo Therapeutics, Inc.
Lipac Oncology LLC
Eli Lilly and Company
University of California, Irvine
Advanced Accelerator Applications
Endocyte
Stanford University
Novartis
Algemeen Ziekenhuis Maria Middelares
Poseida Therapeutics, Inc.
Sharp HealthCare
University Teaching Hospital Hall in Tirol
Regina Elena Cancer Institute
VA Greater Los Angeles Healthcare System
Mabwell (Shanghai) Bioscience Co., Ltd.